Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop disease-causing autoantibodies that specifically target the MuSK protein in the neuromuscular junction.
A clinical research study is a medical study that helps to answer important questions about an investigational medication or product, such as:
All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.
This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. It is sponsored by Cabaletta Bio, Inc. About 24 people with MuSK MG are expected to take part.
MuSK-CAART an investigational cell therapy that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Treatment with MuSK-CAART may potentially lead to complete and durable remission of disease.
You may be able to take part if:
Are you wondering if this clinical trial is right for you? A representative from the Cabaletta Study Team would be glad to discuss the study with you.
Cabaletta Study Team:
*Please include only your name and telephone number in the email. Someone from the Cabaletta Study Team will contact you to discuss the study.